Keyphrases
Anti-VEGF Monoclonal Antibody
33%
Antiangiogenic
100%
Antiangiogenic Agents
33%
Biocompatibility
33%
Biophysical Characterization
33%
Clinical Targets
33%
Diabetic Retinopathy
33%
Extended Period
33%
In Vitro Assay
33%
In Vivo Implantation
33%
Injectability
33%
Injectable Hydrogel
66%
Nanofibrous
100%
Neovascular Disease
33%
Pathological Neovascularization
33%
Peptide Backbone
33%
Peptide Hydrogel
100%
Posterior Segment Diseases
33%
Rheometric
33%
Self-assembly
100%
Vascularization
33%
Vitreous Humor
33%
Medicine and Dentistry
Angiogenesis Inhibitor
33%
Antiangiogenic
100%
Biocompatibility
33%
Diabetic Retinopathy
33%
Disease
66%
Humor
33%
In Vitro
33%
Monoclonal Antibody
33%
Spine
33%
Vascularity
33%
Vasculotropin
33%
Vitreous
33%
Pharmacology, Toxicology and Pharmaceutical Science
Angiogenesis Inhibitor
33%
Antiangiogenic
100%
Biocompatibility
33%
Diabetic Retinopathy
33%
Disease
66%
Monoclonal Antibody
33%
Neovascularization (Pathology)
33%
Vasculotropin
33%